- Home
- Publications
- Publication Search
- Publication Details
Title
Early market access of cancer drugs in the EU
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 27, Issue 1, Pages 96-105
Publisher
Oxford University Press (OUP)
Online
2015-10-22
DOI
10.1093/annonc/mdv506
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
- (2015) N. I. Cherny et al. ANNALS OF ONCOLOGY
- From adaptive licensing to adaptive pathways: Delivering a flexible life-span approach to bring new drugs to patients
- (2015) H-G Eichler et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Approvals of drugs with uncertain benefit–risk profiles in Europe
- (2015) Rita Banzi et al. European Journal of Internal Medicine
- American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
- (2015) Lowell E. Schnipper et al. JOURNAL OF CLINICAL ONCOLOGY
- The Project Data Sphere Initiative: Accelerating Cancer Research by Sharing Data
- (2015) A. K. Green et al. ONCOLOGIST
- Why do cancer drugs get such an easy ride?
- (2015) D. W. Light et al. BMJ-British Medical Journal
- Why do cancer drugs get such an easy ride?
- (2015) D. W. Light et al. BMJ-British Medical Journal
- Accelerated Access to Innovative Medicines for Patients in Need
- (2014) L G Baird et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes
- (2014) Lee M. Ellis et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of benefits and risks in development of targeted therapies for cancer - The view of regulatory authorities
- (2014) Francesco Pignatti et al. Molecular Oncology
- FDA's post-approval studies continue to suffer delays and setbacks
- (2014) Cassandra Willyard NATURE MEDICINE
- Reevaluating the Accelerated Approval Process for Oncology Drugs
- (2013) W. H. Wilson et al. CLINICAL CANCER RESEARCH
- Accelerated Approval and Breakthrough Therapy Designation: Oncology Drug Development on Speed?
- (2013) J. C. Yao et al. CLINICAL CANCER RESEARCH
- Developing Standards for Breakthrough Therapy Designation in Oncology
- (2013) S. J. Horning et al. CLINICAL CANCER RESEARCH
- Cancer Drugs in the United States: Justum Pretium—The Just Price
- (2013) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Expediting Drug Development — The FDA's New “Breakthrough Therapy” Designation
- (2013) Rachel E. Sherman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Temporary Authorization for Use: Does the French Patient Access Programme for Unlicensed Medicines Impact Market Access After Formal Licensing?
- (2013) Albane Degrassat-Théas et al. PHARMACOECONOMICS
- Can Expedited FDA Drug Approval Without Expedited Follow-up Be Trusted?
- (2013) Daniel Carpenter JAMA Internal Medicine
- Evidence vs. Access: Can Twenty-First-Century Drug Regulation Refine the Tradeoffs?
- (2012) J Woodcock CLINICAL PHARMACOLOGY & THERAPEUTICS
- Hurdles in anticancer drug development from a regulatory perspective
- (2012) Bertil Jonsson et al. Nature Reviews Clinical Oncology
- Equipoise: asking the right questions for clinical trial design
- (2012) Steven Joffe et al. Nature Reviews Clinical Oncology
- France's New Framework for Regulating Off-Label Drug Use
- (2012) Joseph Emmerich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Relative Effectiveness Assessment of Pharmaceuticals: Similarities and Differences in 29 Jurisdictions
- (2012) Sarah Kleijnen et al. VALUE IN HEALTH
- Additional safety risk to exceptionally approved drugs in Europe?
- (2011) Arna H. Arnardottir et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- The European Medicines Agency: An Overview of Its Mission, Responsibilities, and Recent Initiatives in Cancer Drug Regulation
- (2011) Francesco Pignatti et al. CLINICAL CANCER RESEARCH
- Despite Criticism Of The FDA Review Process, New Cancer Drugs Reach Patients Sooner In The United States Than In Europe
- (2011) Samantha A. Roberts et al. HEALTH AFFAIRS
- Balancing Access and Evaluation in the Approval of New Cancer Drugs
- (2011) Franklin G. Miller JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic Drugs
- (2011) Eitan Amir et al. JOURNAL OF CLINICAL ONCOLOGY
- Accelerated Approval of Oncology Drugs: Can We Do Better?
- (2011) Susan S. Ellenberg JNCI-Journal of the National Cancer Institute
- Accelerated Approval of Oncology Products: The Food and Drug Administration Experience
- (2011) John R. Johnson et al. JNCI-Journal of the National Cancer Institute
- Role of randomized phase III trials in an era of effective targeted therapies
- (2011) Manish R. Sharma et al. Nature Reviews Clinical Oncology
- Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response
- (2011) Hans-Georg Eichler et al. NATURE REVIEWS DRUG DISCOVERY
- Early Accelerated Approval for Highly Targeted Cancer Drugs
- (2011) Bruce A. Chabner NEW ENGLAND JOURNAL OF MEDICINE
- Conditional Approval and Approval Under Exceptional Circumstances as Regulatory Instruments for Stimulating Responsible Drug Innovation in Europe
- (2010) W P C Boon et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Accelerated Approval and Oncology Drug Development Timelines
- (2010) Michael L. Lanthier et al. JOURNAL OF CLINICAL ONCOLOGY
- European network for Health Technology Assessment, EUnetHTA: Planning, development, and implementation of a sustainable European network for Health Technology Assessment
- (2009) Finn Børlum Kristensen et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Accelerated Approval of Cancer Drugs: Improved Access to Therapeutic Breakthroughs or Early Release of Unsafe and Ineffective Drugs?
- (2009) Elizabeth A. Richey et al. JOURNAL OF CLINICAL ONCOLOGY
- Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma
- (2008) Hans-Georg Eichler et al. NATURE REVIEWS DRUG DISCOVERY
- Drug-Review Deadlines and Safety Problems
- (2008) Daniel Carpenter et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More